DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
it's - 4 Eli Lilly - 4 Altimmune - 3 — - 2 Scott Harris - 2 they've - 2 Morgan Stanley - 2 Drugmakers Eli Lilly - 1
Top related locs:
Altimmune GLP Altimmune's Novo Texas China Wells Fargo Norfolk
Top related orgs:
Novo Nordisk - 3 Marvell Technology - 2 Pfizer - 2 Mines - 1 Eagle Mines - 1 CVR Energy - 1 Service - 1 Novo Nordisk's Ozempic - 1

Search resuls for: "Altimmune's"


8 mentions found


☆ Cramer's Lightning Round: Quanta Services is 'terrific'
  + stars: | 2024-05-06 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon AeroVironment's year-to-date stock performance. Stock Chart Icon Stock chart icon Nutanix's year-to-date stock performance. Stock Chart Icon Stock chart icon Altimmune's year-to-date stock performance. Stock Chart Icon Stock chart icon CVR Energy's year-to-date stock performance. Stock Chart Icon Stock chart icon Quanta Services' year-to-date stock performance.
Persons: it's Organizations: Mines, Eagle Mines, CVR Energy
☆ A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
  + stars: | 2024-03-29 | by ( Hilary Brueck | ) www.businessinsider.com   time to read: +3 min
A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does. That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide). This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication. Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.
Persons: Drugmakers Eli Lilly, —, Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis Organizations: Novo Nordisk, Service Locations: Altimmune, GLP
☆ Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
  + stars: | 2024-03-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Some health experts have said that obesity drugs could shrink critical muscle mass, which could raise the risk of injuries and decrease strength. Those results are similar to those often seen with diet and exercise programs for weight loss. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss." For example, Eli Lilly is testing whether combining its weight loss drug with a monoclonal antibody from Versanis Bio might help patients lose weight while preserving muscle mass. The pharmaceutical giant recently acquired Versanis, which is part of a slate of companies targeting the muscle-loss aspect of weight loss.
Persons: Altimmune, Eli Lilly, Scott Harris Organizations: Novo Nordisk, Novo Nordisk's Ozempic Locations: Altimmune's, Novo
☆ Cramer's Lightning Round: Datadog is a 'dynamite company'
  + stars: | 2024-03-18 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Marvell Technology's year-to-date stock performance. Stock Chart Icon Stock chart icon Datadog's year-to-date stock performance. Stock Chart Icon Stock chart icon Altimmune's year-to-date stock performance. Stock Chart Icon Stock chart icon Lantheus' year-to-date stock performance. Stock Chart Icon Stock chart icon SoFi's year-to-date stock performance.
Persons: Marvell, Centrus, it's, Eli Lilly, Lantheus, they've, Jim Cramer's Organizations: Marvell Technology, Centrus, GE
☆ Cramer's Lightning Round: Affirm is a buy
  + stars: | 2024-02-12 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Vertiv's year-to-date stock performance. Stock Chart Icon Stock chart icon General Dynamics' year-to-date stock performance. Stock Chart Icon Stock chart icon C3.ai's year-to-date stock performance. Stock Chart Icon Stock chart icon Altimmune's year-to-date stock performance. Stock Chart Icon Stock chart icon Affirm's year-to-date stock performance.
Persons: it's, Tom Siebel, Tom, You've Organizations: Dynamics
☆ Stocks making the biggest moves midday: Tesla, Disney, Alibaba, Ulta Beauty and more
  + stars: | 2023-12-01 | by ( Samantha Subin | ) www.cnbc.com   time to read: +4 min
Ulta Beauty — The beauty stock rallied nearly 11% after posting third-quarter results that surpassed analysts' estimates. Samsara — Samsara shares popped 16% after the cloud company posted better-than-expected quarterly results and shared stronger-than-expected guidance. The chip company posted third-quarter earnings that topped Wall Street's estimates but shared weaker-than-expected guidance for the current quarter. Ambarella — Shares slipped 1% after Ambarella reported third-quarter gross margins of 62.6%, down from 63.5% in the year-ago period. Otherwise, the semiconductor design company posted quarterly results that topped estimates.
Persons: Tesla, Nelson Peltz, Alibaba, Morgan Stanley, Wells, Dell, Altimmune, Ambarella, Jefferies, Yun Li, Michelle Fox, Sarah Min, Alex Harring, Brian Evans, Jesse Pound Organizations: Disney — Disney, Trian Fund Management, Pfizer, Paramount Global, Street Journal, Paramount, Apple, Marvell Technology, Invest, Nasdaq, Dell —, LSEG, JPMorgan, Norfolk Southern, Bank of America, CSG Locations: Texas, China, Wells Fargo, Norfolk, Ohio
☆ The options for weight loss treatment are about to explode. These are the companies investors need to know
  + stars: | 2023-07-03 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +14 min
Wegovy was approved as an obesity treatment in June 2021 , but Ozempic, a Type 2 diabetes treatment, has been used off-label for weight loss. Mounjaro uses GLP-1 and gastric inhibitory polypeptide, or GIP, to help patients lose weight. Eli Lilly's oral drug, orforglipron, has an even better profile . They also could be helpful in assisting patients in maintaining weight loss after they've used the injectable versions, he said. Some have highlighted that oral drugs also may be more manageable for patients who can't handle the idea of giving themselves a once-a-week injection.
Persons: Eli Lilly, we're, Jonathan Wolleben, Wegovy, Lilly's tirzepatide, It's, Mounjaro, Wolleben, Eli Lilly's tirzepatide, Lilly, —, Novo, Eli, it's, they've, FactSet, Altimmune's pemvidutide, Morgan Stanley, Mark Purcell, Purcell, Graig Suvannavejh, Suvannavejh, Roth, Dylan Dupuis, Dupuis, Trung Huynh, Goldman Sachs, Chris Shibutani, Shibutani Organizations: Novo Nordisk, JMP Securities, Citizens Company, Nordisk's Ozempic, Food and Drug Administration, Nordisk, Novo, Zealand Pharma, Shandong Suncadia, GSBR, Biosciences, Fujian Shengdi Pharmaceutical, Mizuho Securities, Terns Pharmaceuticals, American Diabetes Association, Viking Therapeutics, Pfizer, Credit Suisse, AstraZeneca, Therapeutics, Medicare, Medicaid, CNBC Pro's Locations: Danish, Shandong, Fujian, Viking
☆ Altimmune's obesity drug safety concerns shrink shares
  + stars: | 2023-03-21 | by ( Bhanvi Satija Sriparna Roy | Bhanvi Satija | Sriparna Roy | ) www.reuters.com   time to read: +2 min
March 21 (Reuters) - Altimmune Inc's (ALT.O) experimental obesity drug helped reduce weight by over 10% on average in a mid-stage trial, the company said on Tuesday, but safety concerns sent its shares tumbling more than 50%. Wolleben added that the drug showed " a little bit worse" tolerability than previous data. Patients who received a 2.4 milligram dose of Altimmune's experimental drug, pemvidutide, achieved average weight loss of 10.7% at the end of week 24, the company said. The data looked competitive to mid-stage data from Novo Nordisk's (NOVOb.CO) obesity drug Wegovy and Eli Lilly's (LLY.N) candidate for the condition, most analysts said. While Novo Nordisk's drug Wegovy is already available, Lilly expects approval for its obesity drug candidate, tirzepatide, this year.
0 next >>
Total: 8